cas 35292-54-7|| where to buy 1-(4-methoxyphenyl)-1-methylhydrazine

Название продукции:1-(4-methoxyphenyl)-1-methylhydrazine

IUPAC Name:1-(4-methoxyphenyl)-1-methylhydrazine

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM1075213-1g	in stock	ƚŪƐŸ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 35292-54-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:35292-54-7; Молекулярная формула:C8H12N2O; Точка плавления:-; Smiles-код:O(C1=CC=C(C=C1)N(N)C)C; Плотность:

: Номер в каталоге:CM1075213; Молекулярная масса:152.2; Точка кипения:; Номер Mdl:; Хранение:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Buntanetap; Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. As the world ages, the demand for Alzheimer's disease (AD) drugs increases dramatically. Alzheimer's disease (AD) will also continue to be an industry focus in 2024. There are various types of AD drugs, including vaccines, monoclonal antibodies, and small molecule inhibitors. Lecanemab has become the first new AD treatment to be fully approved by the FDA in 20 years. Lilly's AD treatment donanemab is under review by the FDA. Among small molecule drugs, buntanetap is a a novel translational inhibitor developed by Annovis. Buntanetap reduces levels of multiple neurotoxic proteins (beta amyloid, tau, alpha synuclein, and TDP43), thereby improving synaptic transmission and axonal transport and reducing inflammation, which has been shown to be a cause of cell death reason. By attacking multiple pathways associated with neurodegeneration, buntanetap can reverse Alzheimer's disease's devastating effects on thinking and memory.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.